The pro-forms of insulin-like growth factor i (igf-i) are predominant in skeletal muscle and alter igf-i receptor activation

Endocrinology

Volumn 154, Issue 3, 2013, Pages 1215-1224

  Durzynska, Julia ^a   Philippou, Anastassios ^a   Brisson, Becky K ^a   Nguyen McCarty, Michelle ^a   Barton, Elisabeth R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FURIN; GLYCOSIDASE; LIGAND; PEPTIDE E; SOMATOMEDIN C;

ARTICLE; BIOLOGICAL ACTIVITY; CELL STRAIN 3T3; ENZYME ACTIVATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; TRANSIENT TRANSFECTION; VIRUS EXPRESSION;

3T3 CELLS; ANIMALS; FURIN; GLYCOSYLATION; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; MUSCLE, SKELETAL; PROTEIN PRECURSORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTOR, IGF TYPE 1; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 84874588994     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1992     Document Type: Article

References (26)

1. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137-148.
2. ColemanME,DeMayoF, Yin KC, et al. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 1995; 270:12109-12116.
3. Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195-200.
4. Barton ER. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J Appl Physiol. 2006;100:1778-1784.
5. Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA. 1998;95:15603-15607.
6. Stevens-Lapsley JE, Ye F, Liu M, et al. Impact of viral-mediated IGF-I gene transfer on skeletal muscle following cast immobilization. Am J Physiol Endocrinol Metab. 2010;299:E730-E740.
7. AdamsGR,McCueSA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol. 1998;84:1716-1722.
8. Lynch GS, Cuffe SA, Plant DR, Gregorevic P. IGF-I treatment improves the functional properties of fast-and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul Disord. 2001;11:260-268.
9. Barton ER. The ABCs of IGF-I isoforms: Impact on muscle hypertrophy and implications for repair. Appl Physiol Nutr Metab. 2006; 31:791-797.
10. Duguay SJ, Milewski WM, Young BD, Nakayama K, Steiner DF. Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases. J BiolChem. 1997;272: 6663-6670.
11. Conover CA, Baker BK, Bale LK, Clarkson JT, Liu F, Hintz RL. Human hepatoma cells synthesize and secrete insulin-like growth factor Ia prohormone under growth hormone control. Regul Pept. 1993;48:1-8.
12. Conover CA, Baker BK, Hintz RL. Cultured human fibroblasts secrete insulin-like growth factor IA prohormone. J Clin Endocrinol Metab. 1989;69:25-30.
13. Wilson HE, Westwood M, White A, Clayton PE. Monoclonal antibodies to the carboxy-terminal Ea sequence of pro-insulin-like growth factor-IA (proIGF-IA) recognize proIGF-IA secreted by IM9 B-lymphocytes. Growth Horm IGF Res. 2001;11:10-17.
14. Bach MA, Roberts CT Jr, Smith EP, LeRoith D. Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Mol Endocrinol. 1990;4:899-904.
15. Barton ER, DeMeo J, Lei H. The insulin-like growth factor (IGF)-I E-peptides are required for isoform-specific gene expression and muscle hypertrophy after local IGF-I production. J Appl Physiol. 2010;108:1069-1076.
16. Forbes BE, Hartfield PJ, McNeil KA, et al. Characteristics of binding of insulin-like growth factor (IGF)-I and IGF-II analogues to the type 1 IGF receptor determined by BIAcore analysis. Eur J Biochem. 2002;269:961-968.
17. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: Implications for drug design. Nat Rev Drug Discov. 2002; 1:769-783.
18. Metzger F, Sajid W, Saenger S, et al. Separation of fast from slow anabolism by site-specific PEGylation of insulin-like growth factor I (IGF-I). J Biol Chem. 2011;286:19501-19510.
19. Pfeffer LA, Brisson BK, Lei H, Barton ER, The insulin-like growth factor-I E-peptides modulate cell entry of the mature IGF-I protein. Mol Biol Cell. 2009;20:3810-3817.
20. Brisson BK, Barton ER. Insulin-like growth factor-I E-peptide activity is dependent on the IGF-I receptor. PLoS ONE. 2012;7: E45588.
21. Denley A, Wang CC, McNeil KA, et al. Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: Correlation with effects on growth and development. Mol Endocrinol. 2005;19:711-721.
22. Blat C, Villaudy J, Delbe J, Troalen F, Golde A, Harel L. Purification from transformed mouse fibroblast of a cell growth inhibitor which is an IGF-binding protein. Growth Factors. 1992;6:65-75.
23. Vajdos FF, Ultsch M, Schaffer ML, et al. Crystal structure of human insulin-like growth factor-1: Detergent binding inhibits binding protein interactions. Biochemistry. 2001;40:11022-11029.
24. Hede MS, Salimova E, Piszczek A, et al. E-Peptides control bioavailability of IGF-1. PLoS ONE. 2012;7:e51152.
25. WallisM.Newinsulin-like growth factor (IGF)-precursor sequences from mammalian genomes: The molecular evolution of IGFs and associated peptides in primates. Growth Horm IGF Res. 2009;19: 12-23.
26. Yuasa K,MasudaT, Yoshikawa C,NagahamaM,Matsuda Y, Tsuji A. Subtilisin-like proprotein convertase PACE4 is required for skeletal muscle differentiation. J Biochem. 2009;146:407-415.